EBS vs JNJ · rev $390.4M vs P/E 17, rev $49.37B
Emergent Biosolutions Inc (EBS) versus Johnson & Johnson (JNJ) — a side-by-side from cached financials, not a winner call.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Latest reported EBS revenue for 2026-06-30 was $390.4M. Net income was -$173.4M. EBS currently screens at market cap $416.4M.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
EBS currently screens at market cap $416.4M. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Not investment advice. Open the EBS and JNJ stock pages for the full models.
Not investment advice.